References
- Josting A DV, Engert A. Methotrexat-pharmakologie. Toxizitaet und rescue-massnahmen bei hochdosierter behandlung. Onkologe 1998; 4: 974–985
- Bleyer W A. The clinical pharmacology of methotrexate: new applications of an old drug. Cancer 1978; 41: 36–51
- Ackland S P, Schilsky R L. High-dose methotrexate: a critical reappraisal. J Clin Oncol 1987; 5: 2017–2031
- Frei E, III, Blum R H, Pitman S W, Kirkwood J M, Henderson I C, Skarin A T, et al. High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity. Am J Med 1980; 68: 370–376
- Josting A, Rudolph C, Mapara M, Glossmann J P, Sienawski M, Sieber M, et al. Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann Oncol 2005; 16: 116–123
- Van Den Berg H W, Murphy R F, Kennedy D G. Rapid plasma clearance and reduced rate and extent of urinary elimination of parenterally administered methotrexate as a result of severe vomiting and diarrhoea. Cancer Chemother Pharmacol 1980; 4: 47–48
- Chabner B A, Young R C. Threshold methotrexate concentration for in vivo inhibition of DNA synthesis in normal and tumorous target tissues. J Clin Invest 1973; 52: 1804–1811
- Howell S B, Ensminger W D, Krishan A, Frei E, III. Thymidine rescue of high-dose methotrexate in humans. Cancer Res 1978; 38: 325–330
- Buchen S, Ngampolo D, Melton R G, Hasan C, Zoubek A, Henze G, et al. Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure. Br J Cancer 2005; 92: 480–487
- Krause A S, Weihrauch M R, Bode U, Fleischhack G, Elter T, Heuer T, et al. Carboxypeptidase-G2 rescue in cancer patients with delayed methotrexate elimination after high-dose methotrexate therapy. Leuk Lymphoma 2002; 43: 2139–2143